SoftBank and Hanwha-backed biomanufacturer Zymergen floated at the top of its range in an upsized offering following over $870m in venture funding.
Zymergen, the US-based biomanufacturer backed by telecommunications and internet group SoftBank and conglomerate Hanwha, is going public today in a $500m initial public offering on the Nasdaq Global Select Market.
The offering consists of just over 16.1 million shares, upsized from an initial allocation of 13.6 million and priced at the top of its $28 to $31 range. Its shares are trading at $39.45 at time of publication, giving it a market capitalisation of more than $3.8bn.
Founded in 2013,…
